{"disease":{"id":"newly-diagnosed-acute-myeloid-leukemia-aml","name":"newly diagnosed acute myeloid leukemia aml"},"drugs":{"marketed":[{"drug_id":"gemtuzumab","indication_name":"newly-diagnosed CD33-positive acute myeloid leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"GEMTUZUMAB","company_name":"Wyeth Pharms Inc","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"100","mechanism":"Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02632708","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03173248","title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":true},{"nct_id":"NCT07514936","title":"Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05445154","title":"SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT05577611","title":"An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT07172204","title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}